These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 38994687)

  • 1. Progress with polo-like kinase (PLK) inhibitors: a patent review (2018-present).
    Bian S; Zhang R; Nie J; Zhu M; Xie Z; Liao C; Wang Q
    Expert Opin Ther Pat; 2024 Sep; 34(9):789-806. PubMed ID: 38994687
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-mitotic functions of polo-like kinases in cancer cells.
    Raab CA; Raab M; Becker S; Strebhardt K
    Biochim Biophys Acta Rev Cancer; 2021 Jan; 1875(1):188467. PubMed ID: 33171265
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular and enzoinformatics perspectives of targeting Polo-like kinase 1 in cancer therapy.
    Shakil S; Baig MH; Tabrez S; Rizvi SMD; Zaidi SK; Ashraf GM; Ansari SA; Khan AAP; Al-Qahtani MH; Abuzenadah AM; Chaudhary AG
    Semin Cancer Biol; 2019 Jun; 56():47-55. PubMed ID: 29122685
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential Cellular Effects of Plk1 Inhibitors Targeting the ATP-binding Domain or Polo-box Domain.
    Shin SB; Woo SU; Yim H
    J Cell Physiol; 2015 Dec; 230(12):3057-67. PubMed ID: 25975351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polo-like kinases inhibitors.
    Garuti L; Roberti M; Bottegoni G
    Curr Med Chem; 2012; 19(23):3937-48. PubMed ID: 22709006
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plk1-targeted small molecule inhibitors: molecular basis for their potency and specificity.
    Murugan RN; Park JE; Kim EH; Shin SY; Cheong C; Lee KS; Bang JK
    Mol Cells; 2011 Sep; 32(3):209-20. PubMed ID: 21809214
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting polo-like kinase 1: advancements and future directions in anti-cancer drug discovery.
    Raab M; Becker S; Sanhaji M
    Expert Opin Drug Discov; 2024 Oct; 19(10):1153-1157. PubMed ID: 39075888
    [No Abstract]   [Full Text] [Related]  

  • 8. Thoughts on the current assessment of Polo-like kinase inhibitor drug discovery.
    Strebhardt K; Becker S; Matthess Y
    Expert Opin Drug Discov; 2015 Jan; 10(1):1-8. PubMed ID: 25263688
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nonpeptidic, Polo-Box Domain-Targeted Inhibitors of PLK1 Block Kinase Activity, Induce Its Degradation and Target-Resistant Cells.
    Chapagai D; Ramamoorthy G; Varghese J; Nurmemmedov E; McInnes C; Wyatt MD
    J Med Chem; 2021 Jul; 64(14):9916-9925. PubMed ID: 34210138
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modelling the Functions of Polo-Like Kinases in Mice and Their Applications as Cancer Targets with a Special Focus on Ovarian Cancer.
    Kressin M; Fietz D; Becker S; Strebhardt K
    Cells; 2021 May; 10(5):. PubMed ID: 34065956
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design and synthesis of a cell-permeable, drug-like small molecule inhibitor targeting the polo-box domain of polo-like kinase 1.
    Srinivasrao G; Park JE; Kim S; Ahn M; Cheong C; Nam KY; Gunasekaran P; Hwang E; Kim NH; Shin SY; Lee KS; Ryu E; Bang JK
    PLoS One; 2014; 9(9):e107432. PubMed ID: 25211362
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of naphthalimide-derivatives as novel PBD-targeted polo-like kinase 1 inhibitors with efficacy in drug-resistant lung cancer cells.
    Li P; Li Y; Ma X; Li L; Zeng S; Peng Y; Liang H; Zhang G
    Eur J Med Chem; 2024 May; 271():116416. PubMed ID: 38657480
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of green tea catechins as potent inhibitors of the polo-box domain of polo-like kinase 1.
    Shan HM; Shi Y; Quan J
    ChemMedChem; 2015 Jan; 10(1):158-63. PubMed ID: 25196850
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure-activity and mechanistic studies of non-peptidic inhibitors of the PLK1 polo box domain identified through REPLACE.
    Craig SN; Baxter M; Chapagai D; Stafford JM; Nurmemmedov E; Altomare D; Wyatt MD; McInnes C
    Eur J Med Chem; 2022 Jan; 227():113926. PubMed ID: 34735919
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of Highly Selective 1,2,3-Triazole-containing Peptidic Polo-like Kinase 1 Polo-box Domain-binding Inhibitors.
    Zhao XZ; Tsuji K; Hymel D; Burke TR
    Molecules; 2019 Apr; 24(8):. PubMed ID: 31014020
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent Advances and New Strategies in Targeting Plk1 for Anticancer Therapy.
    Lee KS; Burke TR; Park JE; Bang JK; Lee E
    Trends Pharmacol Sci; 2015 Dec; 36(12):858-877. PubMed ID: 26478211
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of cyclic peptomer inhibitors targeting the polo-box domain of polo-like kinase 1.
    Murugan RN; Park JE; Lim D; Ahn M; Cheong C; Kwon T; Nam KY; Choi SH; Kim BY; Yoon DY; Yaffe MB; Yu DY; Lee KS; Bang JK
    Bioorg Med Chem; 2013 May; 21(9):2623-34. PubMed ID: 23498919
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent progress in agents targeting polo-like kinases: Promising therapeutic strategies.
    Zhang Z; Xing X; Guan P; Song S; You G; Xia C; Liu T
    Eur J Med Chem; 2021 May; 217():113314. PubMed ID: 33765606
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PLK1 as an oncology target: current status and future potential.
    McInnes C; Wyatt MD
    Drug Discov Today; 2011 Jul; 16(13-14):619-25. PubMed ID: 21601650
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Developments of polo-like kinase 1 (Plk1) inhibitors as anti-cancer agents.
    Li S; Zhang Y; Xu W
    Mini Rev Med Chem; 2013 Dec; 13(14):2014-25. PubMed ID: 24160708
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.